Olema Pharmaceuticals Inc (OLMA) News

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile...

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”...

Form 8-K - Current report

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]